Study of Oral Upadacitinib to Assess Change in Disease Activity and Adverse Events in Adult Participants With Ulcerative Colitis or Crohn's Disease
Launched by ABBVIE · Jun 11, 2024
Trial Information
Current as of August 31, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a medication called upadacitinib to see how well it works for adults with moderate to severe ulcerative colitis or Crohn's disease. Both of these conditions cause long-term inflammation in the digestive system, and the trial aims to find out if upadacitinib can help reduce disease activity and if there are any side effects from the treatment. The study will include about 600 adult participants in Korea who are already prescribed upadacitinib by their doctor.
To be eligible for the trial, participants must have a diagnosis of either ulcerative colitis or Crohn's disease and be suitable for upadacitinib treatment. They should not have any conditions that would prevent them from taking this medication or be involved in other clinical studies. Participants can expect to attend regular check-ups at a hospital or clinic over the course of up to 52 weeks, but there should be no extra burden from participating in this trial.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participants diagnosis with ulcerative colitis or Crohn's Disease suitable for the treatment with Upadacitinib.
- • Participants prescribed upadacitinib in accordance with the approved local label.
- Exclusion Criteria:
- • Participants with any contraindication to Upadacitinib.
- • Participants currently participating in another clinical research not including observational study.
About Abbvie
AbbVie is a global biopharmaceutical company dedicated to developing innovative therapies that address complex health challenges. Founded in 2013 as a spin-off from Abbott Laboratories, AbbVie focuses on key therapeutic areas, including immunology, oncology, neuroscience, and virology. The company is committed to advancing scientific research and delivering groundbreaking treatments that enhance patient outcomes and quality of life. With a robust pipeline and a strong emphasis on collaboration, AbbVie strives to transform the future of medicine through its commitment to clinical excellence and patient-centered approaches.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Daejeon, Daejeon Gwang Yeogsi, Korea, Republic Of
Seoul, Seoul Teugbyeolsi, Korea, Republic Of
Cheonan Si, Chungcheongnamdo, Korea, Republic Of
고양시, Gyeonggido, Korea, Republic Of
Daegu, Gyeongsangbugdo, Korea, Republic Of
Gwangju, Jeonranamdo, Korea, Republic Of
Dongdaemun Gu, Seoul Teugbyeolsi, Korea, Republic Of
Seoul, Seoul Teugbyeolsi, Korea, Republic Of
Seoul, Seoul Teugbyeolsi, Korea, Republic Of
Seoul, Seoul Teugbyeolsi, Korea, Republic Of
Ulsan, Ulsan Gwang Yeogsi, Korea, Republic Of
Daegu, , Korea, Republic Of
중구, , Korea, Republic Of
Seoul, Seoul Teugbyeolsi, Korea, Republic Of
Patients applied
Trial Officials
ABBVIE INC.
Study Director
AbbVie
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported